SVIL2P: A Potential Drug Target and Biomarker for Supervillin Family Members

Target Name: SVIL2P

NCBI ID: G645954

SVIL2P

Other Name(s): supervillin family member 2, pseudogene | Supervillin family member 2, pseudogene | SVILP1

SVIL2P: A Potential Drug Target and Biomarker for Supervillin Family Members

Supervillin family members (SVIs) are a group of proteins that play a critical role in the regulation of cell signaling pathways, including the TGF-β pathway. SVIs are composed of four domains: N-terminal transmembrane domain, a TG-rich region, a coiled-coil domain, and a C-terminal protein-coding domain. SVIs have been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

SVIL2P, a member of the SVI family, has been identified as a potential drug target and biomarker. SVIL2P is a 21-kDa protein that is expressed in various tissues, including brain, heart, and liver. It is highly conserved and has a similar molecular structure to other SVIs, such as SVIN1 and SVIN2.

Functional Analysis of SVIL2P

SVIL2P is involved in the regulation of TGF-β signaling pathway, which is a critical pathway that regulates cell growth, differentiation, and survival. The TGF-β pathway is a complex signaling pathway that is activated by the binding of transforming growth factor (TGF) to its receptor, SMAD2. The TGF-β pathway plays a crucial role in the development and maintenance of tissues and organs, including brain.

SVIL2P is a critical regulator of TGF-β signaling pathway. It is a negative regulator of the TGF-β pathway, which means that it reduces the activity of TGF-β. SVIL2P does this by binding to the TGF-β receptor and preventing it from interacting with SMAD2. This interaction between SVIL2P and TGF-β is critical for the regulation of TGF-β signaling pathway.

SVIL2P has been shown to play a role in the regulation of neural development and plasticity. It has been shown to be involved in the regulation of neuronal differentiation, synaptic plasticity, and memory. SVIL2P has also been shown to be involved in the regulation of pain perception and neuroinflammation.

Potential Therapeutic Applications of SVIL2P

SVIL2P is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. One of the potential therapeutic applications of SVIL2P is the treatment of cancer. SVIL2P has been shown to play a role in the regulation of cell signaling pathways, including the TGF-β pathway. By targeting SVIL2P, researchers may be able to inhibit the activity of TGF-β and reduce the growth and spread of cancer cells.

Another potential therapeutic application of SVIL2P is the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. SVIL2P has been shown to play a role in the regulation of neurodegenerative diseases by regulating the activity of TGF-β. By targeting SVIL2P, researchers may be able to inhibit the activity of TGF-β and reduce the neurotoxicity associated with neurodegenerative diseases.

SVIL2P may also be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The high conservation nature of SVIL2P and its involvement in multiple diseases make it an attractive candidate for biomarker research. By identifying biomarkers associated with SVIL2P, researchers may be able to develop new diagnostic tests and treatments for various diseases.

Conclusion

SVIL2P is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its involvement in the regulation of TGF-β signaling pathway and its potential therapeutic applications make it an attractive candidate for research. Further studies are needed to fully understand the role of SVIL2P in disease and to develop new treatments based on its potential as a drug target and biomarker.

Protein Name: Supervillin Family Member 2, Pseudogene

The "SVIL2P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SVIL2P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets